	A U NI	
	Application No.	Applicant(s)
Nadios of Allows Lille	10/802,024	GRIDNEV ET AL.
Notice of Allowability	Examiner	Art Unit
	Ling-Siu Choi	1713
The MAILING DATE of this communication apperall claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course. THIS
1. \boxtimes This communication is responsive to <u>09/14/2005</u> .		
2. X The allowed claim(s) is/are 1,2,4-8,10-17 and 24-34.		
 3. Acknowledgment is made of a claim for foreign priority unal All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 	been received.	
		
3. Copies of the certified copies of the priority doc	cuments have been received in this	national stage application from the
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.	
(a) ☐ including changes required by the Notice of Draftspers		948) attached
1) hereto or 2) to Paper No./Mail Date		•
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date		office action of
Identifying indicia such as the application number (see 37 CFR 1, each sheet. Replacement sheet(s) should be labeled as such in the		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAL n FOR THE DEPOȘIT OF BIOLOGICA	nust be submitted. Note the AL MATERIAL.
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	atent Application (PTO-152) (PTO-413),
3. ⊠ Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail Dat 8), 7. 🛛 Examiner's Amendn	e
Paper No./Mail Date <u>09/26/05</u>	o), 7. 🖸 Examiner's Amenda	nenvComment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9.	

Art Unit: 1713

DETAILED ACTION

1. This Office action is in response to the Response after Final Rejection filed September 14, 2005. Claims 3 and 23 were canceled and claims 1-2, 4-17, and 24-33 are now pending.

Examiner's Amendment

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CAR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms Gail A. Dalickas on September 30, 2005.

- 3. The application has been amended as follows:
 - Amend the following claim,
- --1. (Currently amended) A process for polymerizing one or more vinylically-unsaturated monomers to form a polymeric product, comprising:

contacting said vinylically-unsaturated monomers with a chain transfer catalyst and a hydrogen atom donor molecule in the absence of conventional free radical initiators, at a temperature from about room temperature to about 240°C, wherein said hydrogen atom donor is selected from dihydronaphthalene, silicon hydrides, tin hydrides, organometallic hydrides,

Art Unit: 1713

benzylic alcohols, hydroquinones, alkyl ether hydroquinones, and benzhydrol. --;

Claim 4, line 1, change "wherein the" to --wherein said--;

Claim 5, line 1, change "The process of Claim 1 or 2 wherein the" to --The process of Claim 1 or 2, wherein said--;

Cancel claim 9 without prejudice;

Claim 10, line 1, change "The process of Claim 9, wherein the" to --The process of Claim 1, wherein said--;

Claim 15, change "The process of claim 12 or 14 wherein the" to --The process of Claim 12, wherein said--;

Claims 16-17, line 1, change "wherein the" to --wherein said--;

Claims 30-32, line 1, change "wherein the" to --wherein said--;

Add the following claim,

--34. (New) The process of Claim 14, wherein said resulting product is terminally unsaturated. --

Allowable Subject Matter

- 4. Claims 1-2, 4-8, 10-17, and 24-34 are allowed.
- 5. The following is an examiner's statement of reasons for allowance:

The present claims are allowable over the closest references: Hawthorne (WO 87/03605) and Muir et al. (US 5,684,101).


Art Unit: 1713

A process to polymerize one or more vinylically-unsaturated monomers, comprising

contacting	the vinylically-unsaturated monomers,
	a chain transfer catalyst, and
	a hydrogen atom donor molecule selected from dihydronaphthalene, silicon
	hydrides, tin hydrides, organometallic hydrides, benzylic alcohols,
	hydroquinones, alkyl ether hydroquinones, and benzhydrol
in the absence	e of conventional free radical initiators
at a temperatu	are from about room temperature to about 240°C

(summary of claim 1)

Hawthorne discloses an oligomer obtained by the free radical polymerization of unsaturated monomers in the presence of a chain transfer agent comprising a transition metal complex of a metal cation and at least one chelating agent, wherein the transition metal complex is represented by the general structure of



wherein R is hydrogen or an organic group; L is a ligand for controlling the stability and electron transfer properties of the transition metal complex having cobalt and a bis(dimethyl glyoxime) ligand (abstract; page 3, lines 5-17; page 4, lines 15-17 and 29-31; page 5, lines 7-8) Hawthorne further disclose that L can be water or an alcohol which reads on hydrogen atom donor molecule (page 5, lines 23-31). Attention is drawn to Example 1, wherein methyl methacrylate (MMA) in benzene is heated in the presence of a cobalt complex obtained by the

contact of cobaltous acetate tetrahydrate, dimethylglyoxime, and pyridine in hydrogen to obtain oligo-MMA. It is noted that no conventional initiator such as AIBN used in Example 2 is used in oligomerization of the unsaturated monomers. However, Hawthorne does not teach or fairly suggest a process comprising the specific hydrogen atom donor molecule.

Muir et al. disclose a process for solution polymerization of MMA in the presence of an azo initiator and Co(II)(diphenanthrenequinone dioxime-diBF₂) as a catalytic chain transfer agent in methylethyl ketone(MEK) (Examples 1-3, C4). However, Muir et al. do not teach or fairly suggest a process comprising the specific hydrogen atom donor molecule in the absence of the conventional free radical initiators.

In light of the above discussion, it is evident as to why the present claims are patentable over the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ling-Siu Choi whose telephone number is 571-272-1098.

If attempt to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu, can be reach on 571-272-1114.

Art Unit: 1713

LING-SUI CHOI
PRIMARY EXAMINER

October 5, 2005